BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20367631)

  • 1. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
    Hubert P; Doyen J; Capelle X; Arafa M; Renoux V; Bisig B; Seidel L; Evrard B; Bousarghin L; Gerday C; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Am J Reprod Immunol; 2010 Aug; 64(2):126-36. PubMed ID: 20367631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
    Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
    Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
    de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
    Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response.
    Dong DD; Yang H; Li K; Xu G; Song LH; Fan XL; Jiang XL; Yie SM
    Reprod Sci; 2010 Aug; 17(8):718-23. PubMed ID: 20445010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia.
    Gill DK; Bible JM; Biswas C; Kell B; Best JM; Punchard NA; Cason J
    J Gen Virol; 1998 Aug; 79 ( Pt 8)():1971-6. PubMed ID: 9714245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
    Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
    Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
    Tsukui T; Hildesheim A; Schiffman MH; Lucci J; Contois D; Lawler P; Rush BB; Lorincz AT; Corrigan A; Burk RD; Qu W; Marshall MA; Mann D; Carrington M; Clerici M; Shearer GM; Carbone DP; Scott DR; Houghten RA; Berzofsky JA
    Cancer Res; 1996 Sep; 56(17):3967-74. PubMed ID: 8752165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of invariant NKT cells with increased IFN-γ production in persistent high-risk HPV-infected high-grade cervical intraepithelial neoplasia.
    Hu T; Yang P; Zhu H; Chen X; Xie X; Yang M; Liu S; Wang H
    Diagn Pathol; 2015 Apr; 10():20. PubMed ID: 25885042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the costimulatory molecule CD86, but not CD80, in keratinocytes of normal cervical epithelium and human papillomavirus-16 positive low squamous intraepithelial lesions.
    Ortiz-Sánchez E; Chávez-Olmos P; Piña-Sánchez P; Salcedo M; Garrido E
    Int J Gynecol Cancer; 2007; 17(3):571-80. PubMed ID: 17386046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
    Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
    Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients.
    Lopez TV; Cancio C; Cruz-Talonia F; Ruiz B; Sapp M; Rocha-Zavaleta L
    FEMS Immunol Med Microbiol; 2008 Nov; 54(2):167-76. PubMed ID: 19049640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions.
    Lee BN; Follen M; Rodriquez G; Shen DY; Malpica A; Shearer WT; Reuben JM
    Cancer; 2006 Sep; 107(5):999-1007. PubMed ID: 16874820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
    Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
    Front Immunol; 2021; 12():768144. PubMed ID: 35095843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPV16 tumor associated macrophages suppress antitumor T cell responses.
    Lepique AP; Daghastanli KR; Cuccovia IM; Villa LL
    Clin Cancer Res; 2009 Jul; 15(13):4391-400. PubMed ID: 19549768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
    Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
    J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.
    Mehlhorn G; Hautmann SK; Koch MC; Strehl JD; Hartmann A; Hilfrich R; Beckmann MW; Griesser H
    Anticancer Res; 2014 Sep; 34(9):5127-32. PubMed ID: 25202103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).
    Sheth SS; Oh JE; Bellone S; Siegel ER; Greenman M; Mutlu L; McNamara B; Pathy S; Clark M; Azodi M; Altwerger G; Andikyan V; Huang G; Ratner E; Kim DJ; Iwasaki A; Levi AW; Buza N; Hui P; Flaherty S; Schwartz PE; Santin AD
    Clin Cancer Res; 2024 May; 30(9):1768-1777. PubMed ID: 38592381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study.
    Wilson LE; Pawlita M; Castle PE; Waterboer T; Sahasrabuddhe V; Gravitt PE; Schiffman M; Wentzensen N
    Int J Cancer; 2013 Nov; 133(9):2172-81. PubMed ID: 23588935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of antibody to E2 protein of human papillomavirus and p16
    Chuerduangphui J; Pientong C; Swangphon P; Luanratanakorn S; Sangkomkamhang U; Tungsiriwattana T; Kleebkaow P; Burassakarn A; Ekalaksananan T
    Med Oncol; 2018 May; 35(6):93. PubMed ID: 29744680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should LSIL-H be a distinct cytology category?: A study on the frequency and distribution of 40 human papillomavirus genotypes in 808 women.
    Zhou H; Schwartz MR; Coffey D; Smith D; Mody DR; Ge Y
    Cancer Cytopathol; 2012 Dec; 120(6):373-9. PubMed ID: 22648956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.